Correction: Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours.
Serrano C, Mariño-Enríquez A, Tao DL, Ketzer J, Eilers G, Zhu M, Yu C, Mannan AM, Rubin BP, Demetri GD, Raut CP, Presnell A, McKinley A, Heinrich MC, Czaplinski JT, Sicinska E, Bauer S, George S, Fletcher JA.
Serrano C, et al. Among authors: fletcher ja.
Br J Cancer. 2019 Jul;121(3):281. doi: 10.1038/s41416-019-0487-5.
Br J Cancer. 2019.
PMID: 31123346
Free PMC article.